

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION No. 813
TO BE ANSWERED ON THE 26th July 2024

Dependency on Import of High Cost Medicines

**813 Dr. Shrikant Eknath Shinde:
Shri Naresh Ganpat Mhaske:
Shri Praveen Patel:
Shri Haribhai Patel:**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the Government has taken into cognizance that India has high dependency on import of high cost medicines;
- (b) if so, the details thereof along with the steps taken/proposed to be taken by the Government to address the issue;
- (c) whether the Government has any scheme to provide incentives to the domestic companies to produce high cost pharmaceutical products in the country;
- (d) if so, the details thereof along with the list of domestic companies which have availed these incentives;
- (e) whether the Government has seen any improvement in domestic production of such medicines through the scheme; and
- (f) if so, the details thereof?

ANSWER

**MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(MS. ANUPRIYA PATEL)**

(a) to (f): India holds the esteemed title of being the pharmacy of the world. It is the third-largest manufacturer of pharmaceuticals by volume. India specialises in generics based formulations which are exported to more than 200 countries.

The export value in drug formulations and biologicals soared from \$11.22 billion in 2014-15 to \$21.71 billion in 2023-24. The import of drug formulations and biologicals during the same period increased more slowly to \$2.50 billion in 2023-24, up from \$1.56 billion in 2014-15. India is, therefore, trade surplus in the pharmaceuticals sector.

The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with the objective to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector. The scheme has financial outlay of Rs. 15,000 crore and tenure up to FY 2027-28. The scheme provides for financial incentive to 55 selected applicants for manufacturing identified products under three categories for a period of six years. The drugs under product categories 1 and 3 such as bio-pharmaceuticals, complex generics, gene therapy drugs, Orphan Drugs, auto-immune drugs,

anti-cancer drugs etc. are being manufactured under the scheme. The drugs under product category 2 include Active Pharmaceuticals Ingredients or their intermediates. Investment worth Rs 29,268 cr have been made by the scheme participants under the scheme. The cumulative sales made under the scheme is Rs 1,61,209 cr, (which includes exports worth Rs 98,837 cr.). Incentive worth Rs. 2,201 cr have been released to the scheme participants. The list of domestic companies which have availed the incentives is enclosed at **Annexure-I**.

Further, the Scheme for Promotion of Research and Innovation in Pharma-Med Tech (PRIP) with an outlay of Rs. 5,000 cr. for a period of 5 years i.e., FY 2023-24 to 2027-28 has been notified. The objective of the scheme is to transform Indian pharmaceutical sector from cost based to innovation-based growth by strengthening the research infrastructure in the country.

List of domestic applicants who have availed the incentive based on approved products under Category 1 and 3 under PLI scheme for Pharmaceuticals:

S. No.	Name of the Applicant
1	Aurobindo Pharma Limited
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Glenmark Pharmaceuticals Limited
5	Intas Pharmaceuticals Limited
6	Lupin Limited
7	Sun Pharmaceutical Industries Limited
8	Torrent Pharmaceuticals Limited
9	Zydus Lifesciences Limited
10	Alembic Pharmaceuticals Limited
11	Biocon Limited
12	Biological E Limited
13	Emcure Pharmaceuticals Limited
14	Macleods Pharmaceuticals Limited
15	MSN Laboratories Private Limited
16	Natco Pharma Limited
17	Strides Pharma Science Limited
18	Aarti Pharmed Labs Limited
19	Aragen Life Sciences Limited
20	BDR Pharmaceuticals International Private Limited
21	Concord Biotech Limited
22	Malladi Drugs & Pharmaceuticals Limited
23	Nosch Labs Private Limited
24	Panacea Biotec Limited
25	Sai Life Sciences Limited
26	Sri Krishna Pharmaceuticals Limited
27	Steril-Gene Life Sciences Private Limited
28	Symbiotec Pharmed Lab Private Limited
29	Umedica Laboratories Private Limited
30	Venus Remedies Limited
31	Symed Labs Limited
32	Abhilash Life Sciences LLP
33	Aurore Life Sciences Private Limited
34	Bal Pharma Limited
35	Biophore India Pharmaceuticals Private Limited
36	Milan Laboratories India Private Limited
37	Neogen Chemicals Limited
38	Optimus Drugs Private Limited
39	Psychotropics India Limited
40	Vandana Life Sciences Private Limited
